The global market for Sepsis Therapeutics is estimated at US$4.6 Billion in 2023 and is projected to reach US$7.1 Billion by 2030, growing at a CAGR of 6.5% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. ![Global Sepsis Therapeutics Market]( "Global Sepsis Therapeutics Market")
The growth in the sepsis therapeutics market is driven by several factors, including technological advancements, increased awareness, and the rising incidence of sepsis worldwide. Technological innovations, such as next-generation sequencing and biomarker discovery, have enhanced our ability to diagnose sepsis early and accurately, facilitating timely intervention with targeted therapies. The global increase in the incidence of sepsis, partly due to the aging population and the prevalence of chronic diseases, has heightened the demand for effective treatments. Furthermore, growing awareness among healthcare professionals and patients about the critical importance of early sepsis management has led to improved diagnostic protocols and more aggressive therapeutic strategies. Additionally, substantial investments in research and development by pharmaceutical companies and government agencies are accelerating the pace of discovery and approval of new sepsis therapies, driving market growth. As a result, the sepsis therapeutics market is poised for significant expansion, offering hope for better management and outcomes for patients affected by this devastating condition.
The growth in the sepsis therapeutics market is driven by several factors, including technological advancements, increased awareness, and the rising incidence of sepsis worldwide. Technological innovations, such as next-generation sequencing and biomarker discovery, have enhanced our ability to diagnose sepsis early and accurately, facilitating timely intervention with targeted therapies. The global increase in the incidence of sepsis, partly due to the aging population and the prevalence of chronic diseases, has heightened the demand for effective treatments. Furthermore, growing awareness among healthcare professionals and patients about the critical importance of early sepsis management has led to improved diagnostic protocols and more aggressive therapeutic strategies. Additionally, substantial investments in research and development by pharmaceutical companies and government agencies are accelerating the pace of discovery and approval of new sepsis therapies, driving market growth. As a result, the sepsis therapeutics market is poised for significant expansion, offering hope for better management and outcomes for patients affected by this devastating condition.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Cephalosporin Drugs segment, which is expected to reach US$3.0 Billion by 2030 with a CAGR of a 6.8%. The Glycopeptide Antibiotics Drugs segment is also set to grow at 6.2% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $1.5 Billion in 2023, and China, forecasted to grow at an impressive 8.4% CAGR to reach $776.3 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Sepsis Therapeutics Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Sepsis Therapeutics Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Sepsis Therapeutics Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as Adrenomed AG, AM-Pharma B.V., Asahi Kasei Pharma America, and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 45 Featured):
- Adrenomed AG
- AM-Pharma B.V.
- Asahi Kasei Pharma America
- Endacea, Inc.
- F. Hoffmann-La Roche Ltd.
- GSK Plc
- InflaRx N.V.
- Inotrem SA
- La Jolla Pharmaceutical Company
- TaiRx, Inc.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISSOUTH KOREAREST OF ASIA-PACIFICIV. COMPETITION
1. MARKET OVERVIEW
- Sepsis: A Life-Threatening Condition Requiring Urgent Action
- Interventions for Managing Sepsis
- Treatments that are Commonly Applied for Sepsis
- Global Economic Update
- Competitive Landscape
- Sepsis Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
- Global Market Prospects and Outlook
- Thriving Global Sepsis Therapeutics Market Oozes Signs of Robust Health
- Cephalosporins Hold a Major Share of the Treatment Market
- Global Sepsis Therapeutics Market Receives Pulsating Impetus from North America, Asia-Pacific to Witness Fastest Growth
- Limited Therapeutic Options: A Challenge
- Antibiotics and Vasopressors - The Current Standard of Care
- Current Categories of Antibacterial Agents for First-line Sepsis Treatment
- Current Anti-bacterial Drugs used in Sepsis
- Current Antifungals used for Sepsis
- GIAPREZA - The Only FDA Approved Branded Drug for Sepsis Treatment
- Promising Treatment for Sepsis
- Recent Market Activity
3. MARKET TRENDS & DRIVERS
- Rising Incidence of Sepsis Propels Market Growth
- Aging Population: A Key Growth Driver for Sepsis Therapeutics
- Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
- A Market Characterized by High Unmet Medical Needs
- Novel Immune-Specific Modes of Action under Focus
- Emphasizing on Endothelial Cell Function
- HMGB1- A Potential Target for Future Therapies
- Hydrocortisone Displays Potential in Septic Shock Treatment
- Reduced Levels of Vitamin C Characterize Sepsis Patients
- Treatment with Hydrocortisone and Vitamin C Demonstrates Positive Impact on Mortality Rate
- Intravenous Vitamins + Hydrocortisone Therapy Causes Waves in the Market
- Anticancer Drugs - Offering Potential Treatment of Sepsis
- New Protein to be Effective for Sepsis
- Rise in Healthcare Expenditure to Drive Growth
- World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
- AI-Driven Sepsis Screening Approach to Save Lives
- Increasing R&D Activity & New Product Launches Spur Market Growth
- Purdue Researchers Develop IV Injection for Sepsis
- PLK1-mTOR Axis - A Potential Therapeutic for Sepsis
- New Nanoparticles - A Revolution in the Development of Clinical Sepsis Therapy
- Strong Pipeline and Increased Research Activity Enables Increased Awareness of Disease Pathogenesis
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Sepsis Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
- Table 2: World Recent Past, Current & Future Analysis for Sepsis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
- Table 3: World Historic Review for Sepsis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 4: World 16-Year Perspective for Sepsis Therapeutics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
- Table 5: World Recent Past, Current & Future Analysis for Cephalosporin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
- Table 6: World Historic Review for Cephalosporin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 7: World 16-Year Perspective for Cephalosporin by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- Table 8: World Recent Past, Current & Future Analysis for Glycopeptide Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
- Table 9: World Historic Review for Glycopeptide Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 10: World 16-Year Perspective for Glycopeptide Antibiotics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- Table 11: World Recent Past, Current & Future Analysis for Aminoglycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
- Table 12: World Historic Review for Aminoglycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 13: World 16-Year Perspective for Aminoglycosides by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- Table 14: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
- Table 15: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 16: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- Table 17: World Recent Past, Current & Future Analysis for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
- Table 18: World Historic Review for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 19: World 16-Year Perspective for Intravenous by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- Table 20: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
- Table 21: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 22: World 16-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
UNITED STATES
- Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
- Table 23: USA Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 24: USA Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 25: USA 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
- Table 26: USA Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 27: USA Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 28: USA 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
CANADA
- Table 29: Canada Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 30: Canada Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 31: Canada 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
- Table 32: Canada Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 33: Canada Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 34: Canada 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
JAPAN
- Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
- Table 35: Japan Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 36: Japan Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 37: Japan 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
- Table 38: Japan Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 39: Japan Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 40: Japan 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
CHINA
- Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
- Table 41: China Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 42: China Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 43: China 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
- Table 44: China Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 45: China Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 46: China 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
EUROPE
- Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
- Table 47: Europe Recent Past, Current & Future Analysis for Sepsis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
- Table 48: Europe Historic Review for Sepsis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 49: Europe 16-Year Perspective for Sepsis Therapeutics by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
- Table 50: Europe Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 51: Europe Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 52: Europe 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
- Table 53: Europe Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 54: Europe Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 55: Europe 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
FRANCE
- Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
- Table 56: France Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 57: France Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 58: France 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
- Table 59: France Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 60: France Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 61: France 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
GERMANY
- Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
- Table 62: Germany Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 63: Germany Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 64: Germany 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
- Table 65: Germany Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 66: Germany Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 67: Germany 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
ITALY
- Table 68: Italy Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 69: Italy Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 70: Italy 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
- Table 71: Italy Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 72: Italy Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 73: Italy 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
UNITED KINGDOM
- Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
- Table 74: UK Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 75: UK Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 76: UK 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
- Table 77: UK Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 78: UK Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 79: UK 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
SPAIN
- Table 80: Spain Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 81: Spain Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 82: Spain 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
- Table 83: Spain Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 84: Spain Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 85: Spain 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
RUSSIA
- Table 86: Russia Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 87: Russia Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 88: Russia 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
- Table 89: Russia Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 90: Russia Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 91: Russia 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
REST OF EUROPE
- Table 92: Rest of Europe Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 93: Rest of Europe Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 94: Rest of Europe 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
- Table 95: Rest of Europe Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 96: Rest of Europe Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 97: Rest of Europe 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
ASIA-PACIFIC
- Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
- Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Sepsis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
- Table 99: Asia-Pacific Historic Review for Sepsis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 100: Asia-Pacific 16-Year Perspective for Sepsis Therapeutics by Geographic Region - Percentage Breakdown of Value Revenues for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
- Table 101: Asia-Pacific Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 102: Asia-Pacific Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 103: Asia-Pacific 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
- Table 104: Asia-Pacific Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
- Table 105: Asia-Pacific Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
- Table 106: Asia-Pacific 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030
AUSTRALIA
- Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
INDIA
- Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
LATIN AMERICA
- Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
MIDDLE EAST
- Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
AFRICA
- Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
Companies Mentioned
- Adrenomed AG
- AM-Pharma B.V.
- Asahi Kasei Pharma America
- Endacea, Inc.
- F. Hoffmann-La Roche Ltd.
- GSK Plc
- InflaRx N.V.
- Inotrem SA
- La Jolla Pharmaceutical Company
- TaiRx, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 291 |
| Published | December 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 4.6 Billion |
| Forecasted Market Value ( USD | $ 7.1 Billion |
| Compound Annual Growth Rate | 6.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
